Literature DB >> 19277419

Subtherapeutic oral anticoagulant therapy: frequency and risk factors.

Eva K Rombouts1, Frits R Rosendaal, Felix J M van der Meer.   

Abstract

Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 - 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 - 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277419

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Clinical validation of a new algorithm for computerized dosing of vitamin K antagonist therapy: a retrospective simulation study.

Authors:  Michela Basileo; Carlo Micheluzzi; Marina Minozzi; Luigi Lazzaroni; Alfonso Iorio
Journal:  Intern Emerg Med       Date:  2011-04-06       Impact factor: 3.397

2.  Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients.

Authors:  Priccila Zuchinali; Gabriela C Souza; Graziella Aliti; Mariana R Botton; Lívia Goldraich; Katia G Santos; Mara H Hutz; Eliane Bandinelli; Luis E Rohde
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

3.  International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation.

Authors:  Winnie W Nelson; Sunita Desai; Chandrasekharrao V Damaraju; Lang Lu; Larry E Fields; Peter Wildgoose; Jeffery R Schein
Journal:  Am J Cardiovasc Drugs       Date:  2015-06       Impact factor: 3.571

4.  Major vessel occlusion may predict subtherapeutic anticoagulation intensity and feasibility of administration of intravenous thrombolytics.

Authors:  Jun Young Chang; Seunguk Jung; Hyun Park; Moon-Ku Han
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.